Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 11-12, 2006, Pages 1092-1097

  Mocroft, Amanda ^a   Rockstroh, Jurgen ^b   Soriano, Vincent ^c   Kirk, Ole ^d   Viard, Jean Paul ^e   Caplinskas, Saulius ^f   Gasiorowski, Jacek ^g   Chiesi, Antonio ^h   Phillips, Andrew N ^a   Lundgren, Jens D ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HVIDOVRE HOSPITAL   (Denmark)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f Lithuanian AIDS Centre   (Lithuania)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INTERFERON; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; EUROPE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; SUPERINFECTION; TREND STUDY; VIRUS LOAD;

ANTIVIRAL AGENTS; EUROPE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES;

EID: 33845300571     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540600786515     Document Type: Article

References (15)

1. Rockstroh, JJ and Mocroft, A and Soriano, V and Tural, C and Losso, MH and Horban, A and (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy J Infect Dis, 192, pp. 992-1002.
2. Greub, G and Ledergerber, B and Battegay, M and Grob, P and Perrin, L and Furrer, H and (2000) Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study Lancet, 356, pp. 1800-5.
3. De Luca, A and Bugarini, R and Cozzi Lepri, A and Puoti, M and Girardi, E and Antinori, A and (2002) Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects Arch Intern Med, 162, pp. 2125-32.
4. Sulkowski, MS and Thomas, DL and Chaisson, RE and Moore, RD. (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B or C virus infection JAMA, 283, pp. 74-80.
5. Nunez, M and Lana, R and Mendoza, JL and Martin-Carbonero, L and Soriano, V. (2001) Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy JAIDS, 27, pp. 426-31.
6. Alberti, A and Clumeck, N and Collins, S and Gerlich, W and Lundgren, J and Palu, G and (2005) Short statement of the First European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients J Hepatol, 42, pp. 615-24.
7. Soriano, V and Garcia-Samaniego, J and Bravo, R and Gonzalez, J and Castro, A and Castilla, J and (1996) Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group Clin Infect Dis, 23, pp. 585-91.
8. Mauss, S and Klinker, H and Ulmer, A and Willers, R and Weissbrich, B and Albrecht, H and (1998) Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count Infection, 26, pp. 16-9.
9. Torriano, FJ and Rodriguez-Torres, M and Rockstroh, JK and Lissen, E and Gonzalez-Garcia, J and Lazzarin, A and (2004) Peginterferon alpha-2a plus ribavarin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med, 351, pp. 451-9.
10. Carrat, F and Bani-Sadr, F and Pol, S and Rosenthal, E and Lunel-Fabiani, F and Morand, P and (2004) Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavarin, for chronic hepatitis C in HIV-infected patients JAMA, 292, pp. 2839-48.
11. Rauch, A and Egger, M and Reichen, J and Furrer, H. (2005) Chronic hepatitis C in HIV infected patients: Low eligibility and applicability of therapy with pegylated interferon-gamma plus ribavarin (letter) JAIDS, 38, pp. 238-40.
12. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barrados M for the VACS-3 project team. Testing, referral and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Inf Dis 2003;36:1039-46.
13. Fleming, CA and Craven, DA and Thornton, D and Tumity, S and Nunes, D. (2003) Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment Clin Inf Dis, 36, pp. 97-100.
14. Mocroft, A and Ledergerber, B and Katlama, C and Kirk, O and Reiss, P and d'Arminio Monforte, A and (2003) Decline in AIDS and death-rates in the EuroSIDA study: An observational study Lancet, 362, pp. 22-9.
15. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O,. Evidence for an increase in the death rate from liver-related disease in patients with HIV: The EuroSIDA study. AIDS 2005;19:2117-25.